01:43 AM EDT, 07/31/2026 (MT Newswires) -- Abivax (ABVX.PA) remains on track to apply for its first new drug application for its ulcerative colitis treatment, obefazimod, by the end of 2026. The late Thursday statement follows the clinical-stage biotechnology company's positive pre-new drug application interaction with the US Food and Drug Administration. Obefazimod aims to treat adult patients with moderately to severely active ulcerative colitis.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.